Biomaterial Database

The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies. 2021

Hermann Einsele, and Javier Briones, and Fabio Ciceri, and Irene García Cadenas, and Fred Falkenburg, and Natacha Bolaños, and H M Mirjam Heemskerk, and Roch Houot, and Michael Hudecek, and Franco Locatelli, and Kate Morgan, and Emma C Morris, and Michael O'Dwyer, and Jordi Gil Sierra, and Marcel van den Brink, and Arjan A van de Loosdrecht

Department of Internal Medicine II, University Hospital Würzburg, Germany.

In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1-2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European Hematology Research. the 11 EHA Research Roadmap sections include normal hematopoiesis; malignant lymphoid diseases; malignant myeloid diseases; anemias and related diseases; platelet disorders; blood coagulation and hemostatic disorders; transfusion medicine; infections in hematology; hematopoietic stem cell transplantation; CAR-T and Other cell-based immune therapies; and gene therapy.